『Chronic hepatitis B treatment ‘Lamifix 100mg’ launched』

 

 

As of September 4, 2012, KyungDong Pharm Co., Ltd. launched a chronic hepatitis B treatmentLamipix tablets 100mg (lamivudine 100mg)’ is released.

 

Lamipix 100mg tablets are a nucleoside antiviral agent containing 100mg of lamivudine, an ingredient whose excellent effectiveness and safety have been proven through more than 10 years of prescription experience in Korea.

 

In addition, it has the effect of preventing damage to liver tissue and preventing hepatitis from worsening into cirrhosis or liver cancer.

 

Ramipix 100mg tablets have been proven to be effective and safe in treating chronic hepatitis B in children, and are the only chronic hepatitis B treatments on the market that can be administered to children over 2 years of age.

 

This product shows a low viral breakthrough phenomenon when administered in combination with Adefovir and is effective against viruses that develop resistance to improve liver function.

 

 

♤ Product Information ♤

 

◇ Product name: Lamifix tablets 100mg

 

◇ Ingredient content: Lamivudine 100 mg

 

◇ Effectiveness

- Inhibits viral proliferation in patients with chronic active hepatitis B virus infection (limited to patients with positive HBV-DNA in the blood)

- When starting chronic hepatitis B treatment for the first time: Since the incidence of resistance is high in patients receiving lamivudine, use of this drug should be considered only when other antiviral agents with a higher genetic barrier to resistance cannot be used or are not appropriate.

 

◇ Appearance: Light orange, rectangular film-coated tablet with convex sides.

 

◇ Dosage and usage

Adults - once a day, 100mg

Children 2-17 years - 3mg/1kg once daily, maximum 100mg per day

 

◇ Insurance price: 2,206 won/tablet

 

◇ Packaging unit: 30 tablets

 

◇ Product code: 648102900

 

※ Please refer to the product manual for other details such as dosage, precautions for use, etc.